Price To Earnings Ratio -32.81 | Sector PE 62.05 |
PB Ratio 4.54 | Sector PB 9.13 |
EPS -30.06 | Dividend Yield 0.00 |
Today's Volume 103.505 K | 5 Day Avg. Volume 194.340 K |
PEG Ratio -1.45 | Market Cap. ₹ 14,810.00 Cr. |
Time | WOCKPHARMA | VS | Industry |
---|---|---|---|
1 Day | 6.26% | 1.58% | |
1 Week | 3.93% | 2.11% | |
1 Month | 1.47% | -1.21% | |
6 Months | 40.89% | 21.8% | |
1 Year | 342.17% | 60.95% |
Period (Days) | SMA | Indication |
---|---|---|
10 | 966.88 | Bullish |
20 | 984.21 | Bullish |
30 | 1003.34 | Bearish |
50 | 985.37 | Bullish |
100 | 841.94 | Bullish |
200 | 681.04 | Bullish |
Annual | FY 2024 | FY 2023 | FY 2022 | ||||
---|---|---|---|---|---|---|---|
Operating Activities | 219.00 | 153.00 | 413.00 | ||||
Investing Activities | -137.00 | -125.00 | -201.00 | ||||
Financing Activities | 334.00 | -315.00 | -71.00 | ||||
Net Cash Flow | 416.00 | -287.00 | 141.00 |
All Figures in ₹ Cr., unless mentioned otherwise
Name | 1D (%) | 1W (%) | 1M (%) | 6M (%) | 1Y (%) |
---|---|---|---|---|---|
Wockhardt | 6.26 | 3.93 | 1.47 | 40.89 | 342.17 |
Alembic | 0.98 | -1.34 | -9.76 | 3.71 | 3.71 |
Aurobindo Pharma | 4.21 | 2.56 | 0.07 | 22.54 | 63.22 |
Fortis Healthcare | -3.82 | 2.44 | 4.16 | 25.9 | 82.15 |
Ajanta Pharmaceuticals | -0.16 | 0.4 | -1.11 | 45.53 | 88.12 |
Wockhardt Limited is a pharmaceutical and biotechnology company. The company's field of activity is the production and distribution of pharmaceutical and biopharmaceutical preparations, active ingredients (API) and vaccines. It produces a variety of dosage forms, including sterile injectable and lyophilized products. The company offers products in the treatment areas of dermatology, cosmetology, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough treatment and diabetology. The company's products across India are Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE, Emrok O , Emrok , FOSCHEK -S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. It has production and research facilities in India, the United States and the United Kingdom, and a manufacturing facility in Ireland.